RxDoctor Payments DataLook up a doctor →

Brenda Sassen, APRN

Family · Lakewood, CONPI 1740614585

Payments from drug & device makers

$14,708in general payments, 2019–2025

Across 748 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$1K
  • Pfizer$880
  • plus $5K from 28 others

What the payments were for

  • Food & beverage$14,53599%
  • Education$1731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,708 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$16,053
Medicare patients
156
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$424,285
Humira(Cf) PenAdalimumab12$77,754
XifaxanRifaximin22$76,370
LinzessLinaclotide35$32,103
MotegrityPrucalopride Succinate13$7,005
Dexlansoprazole DrDexlansoprazole13$3,040
Budesonide DrBudesonide17$2,611
Dicyclomine Hcl59$2,468
Pantoprazole Sodium122$940
CholestyramineCholestyramine (With Sugar)13$751
Azathioprine14$697
Omeprazole50$638
Famotidine34$548
Spironolactone17$127
Furosemide11$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,184$424,28515 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,125$76,37022 claims
AbbVieLinzess$4,082$32,10335 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,430$7,00513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →